Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 8Vincristine 6romidepsin 5Prednisone 5Doxorubicin 5Lenalidomide 4Etoposide 4fludarabine phosphate 3fludarabine 3Rituximab 3Dexamethasone 3Bortezomib 3Azacitidine 3selinexor 2darinaparsin 2carfilzomib 2belinostat 2Oxaliplatin 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Injections 2Gemcitabine 2Depsipeptides 2Dasatinib 2Carboplatin 2Brentuximab Vedotin 2Biopsy 2Bendamustine Hydrochloride 2Alemtuzumab 2umbralisib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Peripheral × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡